SCHEMBL1608540

SCHEMBL1608540

COc1cccc(-c2noc(-c3cnc(F)c(C)c3)n2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 12/20 0.67
▸ RAB9A P51151 12/20 0.67
▸ SMN1; SMN2 Q16637 8/20 0.67
▸ MAPT P10636 7/20 0.67
▸ TP53 P04637 5/20 0.61
▸ CYP1A2 P05177 1/20 0.61
▸ CYP3A4 P08684 1/20 0.61
▸ CYP2D6 P10635 1/20 0.61
▸ CYP2C9 P11712 1/20 0.61
▸ CYP2C19 P33261 1/20 0.61
▸ NFKB1 P19838 3/20 0.61
▸ NFKB2 Q00653 3/20 0.61
▸ RELA Q04206 3/20 0.61
▸ TDP1 Q9NUW8 1/20 0.61
▸ MEN1 O00255 3/20 0.59
▸ KMT2A Q03164 3/20 0.59
▸ MAPK1 P28482 2/20 0.54
▸ PKM P14618 1/20 0.54
▸ GRM5 P41594 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1251096 0.94 NPC1 (0.60) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL1249937 0.86 MAPT (0.60) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL1608528 0.83 NPC1 (0.49) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL1608448 0.81 NPC1 (0.57) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL12420362 0.79 NPC1 (0.88) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL26093743 0.77 RAB9A (0.79) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL1250873 0.76 NPC1 (0.50) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL12692350 0.75 NPC1 (0.86) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL16067423 0.75 L3MBTL1 (0.72) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL8040085 0.74 NPC1 (0.90) NPC1RAB9ASMN1; SMN2MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US claimed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US disclosed
WO-2009146343-A1 NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES MERCK & CO., INC. (US) 2009-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles APP, PSEN1, BACE1 NPC1 129/4885RAB9A 4026/4885SMN1; SMN2 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback